New combo therapy aims to boost survival in tough rectal cancer
NCT ID NCT07549399
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether adding immunotherapy and a targeted drug to short-course radiotherapy and chemotherapy improves outcomes for people with high-risk rectal cancer. About 204 participants will receive either the standard treatment or the intensified combo. The study aims to see if the new approach can reduce cancer recurrence and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Short-course radiotherapy, chemotherapy (mFOLFOX6), immunotherapy (PD-1 antibody), and targeted therapy (cetuximab or bevacizumab based on genetic type)
What this could lead to
If successful, this could offer a more effective neoadjuvant treatment for high-risk rectal cancer, potentially improving survival and reducing recurrence.
What could go wrong
This is an early-stage Phase 3 trial with no results yet. The intense combination therapy may cause significant side effects, and benefits over standard care are not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510065, China
Contact Phone: •••-•••-•••• Email: •••••@•••••